Jan. 21, 2017: This month’s handpicked stories from across the consortium highlight major breakthroughs in diagnostics and treatment; spotlight emerging leaders; and celebrate milestones in funding and expansion. The Big Ten CRC members will continue asking tough questions in 2018; resolve to catch the play-by-play Across the Consortium! Read More
Jan. 8, 2018: The Big Ten Cancer Research Consortium (Big Ten CRC) recently welcomed Salma Jabbour, MD, as a member of its Steering Committee, representing Rutgers Cancer Institute of New Jersey. The committee, composed of one representative from each member institution, meets on a regular basis to review activities of the consortium and decide matters of policy. A radiation oncologist with a subspecialty in lung and gastrointestinal (GI) cancers, and a co-chair of the Read More
Jan. 4, 2018: Applications are due January 15 for a nationwide integrative oncology training program. The Integrative Oncology (IO) Scholars program brings together oncology professors from the Big Ten and beyond, in a free year-long course. Designed for the full spectrum of oncology care professionals, the program equips oncologists, nurses, physician assistants, physical therapists, occupational therapists, social workers, and psychologists with the knowledge and skills necessary to provide safe and evidence-based integration of complementary therapies in conventional oncology care. The course is funded by the National Cancer Institute and developed by researchers and clinicians at the Read More
Dec. 21, 2017: Researchers have made great strides in the fight against cancer through recently approved immunotherapy drugs, including pembrolizumab and nivolumab, drugs that target a specific interaction between cancer cells and T cells. Part of a class of immune therapies known as checkpoint inhibitors, these drugs target the programmed death-1 / programmed death-ligand 1 (PD-1/PD-L1) pathway. PD-1/PD-L1 drugs have led to durable responses in patients whose tumors responded to therapy. “However, most patients with advanced kidney cancer — up to 3 in 4 patients — do not benefit from these drugs,” said Ajjai Alva, MD, of the University of Michigan. “We believe that a significant factor influencing the low response rate can be found within the tumor microenvironment and hope that adding a drug... Read More
Dec. 18, 2017: Get up to date on the latest discoveries and important breakthroughs. Be inspired by accounts of teamwork and generosity. Remember why we are stronger together. All this and more as we take you Across the Consortium! Read More
Dec. 1, 2017:Investigator Spotlight Elizabeth C. Neil, MD, Masonic Cancer Center, University of MinnesotaEducational background: BS, Wayne State University School of Medicine: MD, University of Cincinnati: Residency in adult neurology, Memorial Sloan Kettering Cancer Center: Fellowship in neuro-oncology Research interests: I am a neuro-oncologist at the University of Minnesota. A career focus of mine is to make clinical trials available to my patient population, which includes those diagnosed with primary brain tumors or metastatic disease to the central nervous system. I partake in industry-sponsored, national consortium, and Big Ten Network coordinated clinical trials, as well as... Read More
Nov. 18, 2017: The only thing as exciting as the teams competing on the field is the team fighting cancer - the Big Ten Cancer Research Consortium. The member institutions are driving science rapidly from new ideas to new treatments, and they do not wait for anyone to catch up. So keep up, with this month's Across the Consortium! Read More
Nov. 2, 2017: The Big Ten Cancer Research Consortium recently welcomed as a member of its steering committee Anne Schott, MD, clinical professor of medicine and associate director of clinical research at the University of Michigan Comprehensive Cancer Center. The committee consists of one representative from each member institution and is responsible to decide matters of policy for the consortium. A Gulf Coast native, Schott attended medical school at the University of South Alabama. She completed a medical internship and residency at University of Virginia and then a fellowship in hematology-oncology at the University of Michigan. Read More
Nov. 1, 2017:Investigator Spotlight Dr. Zachary Morris is an Assistant Professor in the Department of Human Oncology at the University of Wisconsin School of Medicine and Public Health and is a member of the UW Carbone Cancer Center. This story is adapted from an earlier version, originally published by UW HealthTeaching the Immune System to Fight Cancer Vaccines against an infection work by training the immune system at the site of injection and then spreading those educated immune cells throughout the body. Read More
Subscribe to the Big Ten CRC Newsletter
X
Facebook
YouTube